<DOC>
	<DOCNO>NCT02135614</DOCNO>
	<brief_summary>This study evaluate antiviral effect , pharmacokinetics , safety , tolerability presatovir respiratory syncytial virus ( RSV ) positive adult hospitalize acute respiratory infectious symptom . Participants receive 1 dose presatovir follow 28 day postdose . Nasal swabs collect study visit ( exclude Day 28 ) assay change viral load primary endpoint .</brief_summary>
	<brief_title>Efficacy , Pharmacokinetics , Safety Presatovir Hospitalized Adults With Respiratory Syncytial Virus ( RSV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>Key Current inpatient New onset acute respiratory infectious symptom , acute worsen chronic symptom relate ongoing respiratory disease â‰¤ 5 day prior screen : Upper respiratory tract symptom : nasal congestion , runny nose , sore throat , earache Lower respiratory tract symptom : cough , sputum production , wheeze , dyspnea , chest tightness Documented RSVpositive current admission within 72 hour screen , evaluate screen Key Related medical history : Pregnant , breastfeeding , lactate female Individuals require &gt; 50 % supplemental oxygen ( individual awake ) screening Individuals Clinical Frailty Scale ( CFS ) &gt; 7 Baseline Known significant abnormality alter anatomy nose nasopharynx , opinion investigator , preclude obtain adequate nasal swab sample either nasal passage Waiting recently ( within past 12 month ) receive bone marrow , stem cell , solid organ transplant , receive radiation chemotherapy within 12 month prior Screening Individuals HIV/AIDS know CD4 count &lt; 200 cells/uL History severe dementia Alzheimer 's disease History drug and/or alcohol abuse , opinion investigator , may prevent adherence study activity Related medical condition screening : Influenzapositive determine local diagnostic test Known Middle East Respiratory Syndrome coronavirus ( MERSCoV ) infection know coinfection coronavirus Use mechanical ventilation current admission , include noninvasive ventilation Clinically significant bacteremia fungemia adequately treat prior Screening , determine investigator Inadequate treatment confirm bacterial , fungal , nonRSV pneumonia , determine investigator Excessive nausea/vomiting admission , determine investigator , preclude administration orally administer study drug Related allergy : Known allergy component study drug ( microcrystalline cellulose , mannitol , croscarmellose sodium , magnesium stearate , polyvinyl alcohol , titanium dioxide , polyethylene glycol talc ) Documented history acute ( anaphylaxis ) delayed ( StevensJohnson syndrome epidermal necrolysis ) allergy sulfa drug Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>